Chinese police yesterday accused a British executive of drugmaker GlaxoSmithKline (GSK) of leading a sprawling scheme to bribe doctors and hospitals to use its products.
The announcement was the first time a foreign employee in China of British-based GSK was accused in the investigation announced in in July last year.
It highlighted the widespread use of payments to doctors and hospitals by sellers of drugs and medical equipment in a state-run and poorly funded health system that Chinese leaders have promised to improve.
The executive, Mark Reilly, is accused of operating a “massive bribery network,” police official Gao Feng (高峰) said at a news conference.
He said the case had been handed over to prosecutors.
Beginning in January 2009, Reilly was accused of ordering his sales team to pay doctors, hospital officials and health institutions to use GSK’s products, said Gao, deputy director of the Chinese Ministry of Public Security’s economic crimes unit.
He said that resulted in “illegal revenue” of hundreds of millions of dollars.
Gao said that as far as he knew, Reilly still was in China, but he had no details of his status.
He said dozens of other people also were implicated, but he gave no names or other details.
Reilly is GSK’s senior vice president of pharmaceuticals for China and Hong Kong and former general manager for China.
Police previously identified four Chinese employees of GSK who they said confessed to bribery.
A second foreign drugmaker, AstraZeneca, said in July last year that police in Shanghai were investigating one of its salespeople.
The company has given no information since then.
Chinese state media have publicized the investigations of GSK and AstraZeneca.
However, economists who study Chinese healthcare say such payments are more widely used by China’s domestic drug manufacturers.
Doctors and hospitals routinely accept informal payments from patients and suppliers of medical goods to top up low salaries and cover gaps in budgets.
Hospitals also raise money by adding surcharges to drug prices and assigning employees sales quotas. That can also distort treatment by encouraging overuse of expensive drugs or procedures.
As a result of bribery, GSK was able to receive prices for its medications that were up to seven times the level of the same products sold in other countries, Gao said.
In a separate statement, police in the central city of Changsha, where the investigation began, said Reilly and two Chinese executives also are accused of bribing government officials in Beijing and Shanghai.
Police in Changsha said last July last year that employees appeared to be trying to evade GSK’s internal anti-bribery controls by making payments totaling as much as 3 billion yuan (US$490 million) to a travel agency that gave back at least part of that money.
One of the detained Chinese employees was shown on state television at that time describing how he paid bribes to government officials to win support for use of the company’s medications.
The British embassy in Beijing said it could not comment while the case was underway and referred questions to GSK.
Gao said possible charges include bribing nongovernment workers and bribing corporate units, while GSK might face charges of corporate bribery.
The company has given the investigation its “full support and assistance,” Gao said.
The investigations coincide with efforts by Chinese Communist Party leaders to improve the nation’s health system and rein in surging costs of medicine and medical care that are fueling public frustration.
Under the current system, the state-set price to see an oncologist or other specialist is as little as 7 yuan, less than the cost of a hamburger and too little to cover a hospital’s expenses.
The top salary for an experienced physician might be as little as 6,000 yuan per month.
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has appointed Rose Castanares, executive vice president of TSMC Arizona, as president of the subsidiary, which is responsible for carrying out massive investments by the Taiwanese tech giant in the US state, the company said in a statement yesterday. Castanares will succeed Brian Harrison as president of the Arizona subsidiary on Oct. 1 after the incumbent president steps down from the position with a transfer to the Arizona CEO office to serve as an advisor to TSMC Arizona’s chairman, the statement said. According to TSMC, Harrison is scheduled to retire on Dec. 31. Castanares joined TSMC in
EUROPE ON HOLD: Among a flurry of announcements, Intel said it would postpone new factories in Germany and Poland, but remains committed to its US expansion Intel Corp chief executive officer Pat Gelsinger has landed Amazon.com Inc’s Amazon Web Services (AWS) as a customer for the company’s manufacturing business, potentially bringing work to new plants under construction in the US and boosting his efforts to turn around the embattled chipmaker. Intel and AWS are to coinvest in a custom semiconductor for artificial intelligence computing — what is known as a fabric chip — in a “multiyear, multibillion-dollar framework,” Intel said in a statement on Monday. The work would rely on Intel’s 18A process, an advanced chipmaking technology. Intel shares rose more than 8 percent in late trading after the
FACTORY SHIFT: While Taiwan produces most of the world’s AI servers, firms are under pressure to move manufacturing amid geopolitical tensions Lenovo Group Ltd (聯想) started building artificial intelligence (AI) servers in India’s south, the latest boon for the rapidly growing country’s push to become a high-tech powerhouse. The company yesterday said it has started making the large, powerful computers in Pondicherry, southeastern India, moving beyond products such as laptops and smartphones. The Chinese company would also build out its facilities in the Bangalore region, including a research lab with a focus on AI. Lenovo’s plans mark another win for Indian Prime Minister Narendra Modi, who tries to attract more technology investment into the country. While India’s tense relationship with China has suffered setbacks